July 1, 2001

Hematologic malignancies

Key Points

Key points are not available for this paper at this time.

Abstract

Division of Hematology, Brigham and Women's Hospital; Howard Hughes Medical Institute; and Harvard Medical School; Boston, Massachusetts, USA. Correspondence to D. Gary Gilliland, PhD, MD, Harvard Institutes of Medicine, 4 Blackfan Circle, Room 418, Boston MA 02115, USA; e-mail: email protected

Bookmark

Cite This Study

D. Gary Gilliland (Sun,) studied this question.

synapsesocial.com/papers/6a1e4a0b4e724749e768a42e https://doi.org/https://doi.org/10.1097/00062752-200107000-00001

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia2001 · 5,240 citations
2

Bookmark

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia2001 · 5,240 citations
2